# Beyond dopamine: exploring endocannabinoids in Parkinson’s disease

## TL;DR

This paper explores the role of endocannabinoids in Parkinson’s disease, suggesting they may play a key role in its development and treatment.

## Contribution

The paper highlights new genetic evidence linking endocannabinoid deficiency to Parkinson’s disease.

## Key findings

- Homozygous loss-of-function variants in DAGLB are linked to early-onset Parkinsonism.
- Deficiency in 2-AG, a major endocannabinoid, is associated with Parkinson’s disease pathology.
- The endocannabinoid system may offer a new therapeutic target for Parkinson’s disease.

## Abstract

Parkinson’s disease (PD) is a prevalent degenerative movement disorder largely attributed to the dysfunction of dopamine transmission in the basal ganglia. However, the role of the endocannabinoid (eCB) system (ECS) in PD pathology and symptomatology is often overlooked in discussions. Recent research, including our own, has identified multiple homozygous loss-of-function variants in diacylglycerol lipase β (DAGLB), an enzyme involved in the synthesis of 2-arachidonoyl-glycerol (2-AG) - the most abundant eCB in the brain - in individuals with early-onset autosomal recessive Parkinsonism. These genetic findings strongly link eCB deficiency with the etiopathogenesis of PD. Exploring the roles of DAGLB and 2-AG signaling in PD and dopamine transmission could provide a new perspective on PD treatments, focusing on the function of the ECS and the pathophysiological implications of its disruption.